GSK back in China via new API manufacturing agreement with Desano

By Zachary Brennan

- Last updated on GMT

GSK back in China via new API manufacturing agreement with Desano

Related tags Manufacturing Pharmacology China

GSK’s HIV unit ViiV Healthcare and China-based Desano Pharmaceuticals have forged an agreement whereby Desano will manufacture the API of GSK’s HIV drug Tivicay (dolutegravir) in China.

Under the agreement, Desano will manufacture the API of dolutegravir before it’s fed into the GSK/ViiV supply chain for future sale in China and other unnamed developing countries. ViiV and Desano are also exploring further options for the manufacture of finished drug products and fixed dose combinations of dolutegravir with APIs.

The partnership marks an important step for GSK in improving its relations with China after the company in September 2014 was fined about $480m for bribing Chinese doctors.

The dolutegravir API will be manufactured at one of Shanghai-based Desano’s three Chinese API manufacturing sites, and will allow ViiV to offer a competitive supply of the finished product for China and other developing countries, subject to national approvals.

"With our recent agreement with the Medicines Patent Pool and our other access initiatives this deal is aligned with our ongoing commitment to improve access to our medicines in countries where the need is greatest​," said Dr Dominique Limet, CEO of ViiV Healthcare.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers